Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. Methods In a 71-week, double-blind, randomized, placebo-controlled trial conducted at 22 sites in four countries, we enrolled persons without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions. The coprimary end points at week 64 were the percent change in body weight and a reduction of 5% or more in body weight; confirmatory secondary end points included reductions in body weight of 10% or more, 15% or more, and 20% or more and the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score. Results A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P Conclusions Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, oral semaglutide 25 mg has been shown to induce a 13.6% WL after 71 weeks in obese individuals with T2DM [141].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [141]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Global burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationTranscellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Self-citationBoye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 88
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
Cited by
Items 101–156 of 156
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Martínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
“Emerging therapies include oral semaglutide and non-peptide incretin agonists such as orforglipron, which may further expand therapeutic options (Wharton et al., 2023; Wharton et al., 2025b).”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“FDA-approved oral semaglutide 25 mg, it reduced body weight by a mean of 13.6% at week 64, compared with 2.2% in the placebo group [27].”
InfluentialKeyserling, T. C., Wu, Q., Ammerman, A. S., Berkowitz, S. A., Buse, J. B., Couper, D. J., Evenson, K. R., Hursting, S., Sotres‐Alvarez, D., Lyons, K. M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29006 · Cited by 1
Reappraising obesity management in the GLP-1 receptor agonist era
Christmas, T., Ahmed, A. R., & Tan, T. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00126-0
Oral semaglutide for obesity: clarifying comparative evidence and real-world applicability
Zou, Y. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2721720
Fu, J., Zhao, X., Liu, J., Yang, Y., & Jiang, H. (2026) · Foods · doi:10.3390/foods15162912
“Despite its therapeutic benefits, semaglutide is associated with gastrointestinal adverse effects, most notably transient nausea and vomiting, which may compromise treatment tolerability and, in some cases, pose additional health risks [5].”
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Prieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Barton, K. I., Boyle, R. J., Dennis, D. A., & Jennings, J. M. (2026) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-25-00892
Pharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
“[13] Since the 25 mg oral formulation showed similar efficacy to 2.4 mg subcutaneous semaglutide used in the STEP 1 study, it was submitted to the U.S. Food and Drug Administration (FDA) for review, which has now been approved for chronic weight management.”
InfluentialSemaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
Arbogast, M., Bayer, M., Biraima, M., Brunner, W., Rabl, C., Gerber, P., & Gerö, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100742
Oral Incretin-Based Therapies for Weight Management
Cheng, H. E., Bonafede, M., & Shukla, A. P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01456-6
“Recent data has also shown that the prevalence of obesity continues to increase at a disproportionately greater rate in low-to-middle income countries [3], which may have poorer access to care and medications.”
InfluentialThe Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
“…by the FDA for weight management, after publication of Phase 3 clinical trial data showing mean weight loss of 13.6% at 64 weeks (estimated treatment difference vs. placebo of − 11.4%), with 60% of oral semaglutide-treated participants (vs 14% with placebo) reaching weight loss of 10% or more [34].”
InfluentialPacific RxTracts - February 2026
RxTracts, P. (2026) · Scholarly Commons (University of the Pacific)
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
“Recent phase III evidence has demonstrated clinically meaningful weight reduction with once-daily oral semaglutide 25 mg in adults with overweight or obesity (95).”
InfluentialHan, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Mackey, S., Egan, C., & Elkind-Hirsch, K. E. (2026) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941261481473
Salcaprozate Sodium as a Permeation Enhancer—Mechanism, Applications and Unresolved Questions
Dinkov, B., Koleva, N., & Stavreva, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091171 · Cited by 1
“The OASIS 4 trial of 25 mg oral semaglutide (71 weeks; n = 307; 2:1 randomization versus placebo) reported a mean change in body weight at week 64 of − 13.6% versus − 2.2% with placebo, with ≥ 10% weight loss in 63.0% and ≥ 20% weight loss in 29.7% of patients [41].”
InfluentialAlmandoz, J. P., Tchang, B. G., Myers, K., Traina, A., Bhavsar, J., Divino, V. M., Kent, C., & Tadesse-Bell, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71318
Kaltsas, A., Gkioxaris, V., Giannakas, T., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187313
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Increased risk of gallstones with obesity and rapid weight loss
Khalil, M., Ciaula, A. D., Baffy, G., Krawczyk, M. J., & Portincasa, P. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102142
Brancato, D., Borretta, G., Chianelli, M., Disoteo, O., Grasso, M., Grimaldi, F., Guastamacchia, E., Muratori, F., Oleandri, S., Orio, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907270
Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity
Meek, C. L., Anjana, R. M., Chandiwana, N. C., Chow, E. W. K., Franco, D. R., Halpern, B., Lamptey, R., Lingvay, I., Ma, R. C. W., Mohan, V., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00228-1
Self-citationVikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Ganjre, S., Borah, L., & Khardenavis, A. (2026) · Cureus · doi:10.7759/cureus.117270
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
“Oral semaglutide 25 mg has further expanded the evidence base for noninjectable treatment, producing 13.6% TBWL in the OASIS 4 trial [29].”
InfluentialNovel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
“Exposure is more variable after oral than subcutaneous administration, although the long half-life attenuates day-to-day fluctua - tions at steady state [ 26].”
Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity
Lei, Y., Tang, H., Jian, X., Asch, D. A., & Chen, Y. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.37779
Paccou, J., Rolvien, T., Hauser, B., Sølling, A. S., Anastasilakis, A. D., & Lems, W. F. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261460301
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Gupta, A. K., Teasell, E. M., Magalhães, R. F., Mirmirani, P., & Piguet, V. (2026) · Medical Sciences · doi:10.3390/medsci14060652
“A higher incidence of dysesthesia-related events was observed with the higher dose formulations, both sub-cutaneous and oral, typically indicated for weight loss [26,27,56–58].”
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
Ard, J. D., & Almandoz, J. P. (2026) · Obesity Reviews · doi:10.1111/obr.70228
Early Uptake of Oral Semaglutide for Obesity Treatment After Regulatory Approval
Jelwan, Y. A., Zahid, S., Burka, S., Silver, N., Dzaye, O. D. A., & Blaha, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-02436
Look, M., Bays, H., le Roux, C. W., Xavier, N., Allen, S. E., Jouravskaya, I., Stefański, A., Dimitriadis, G. K., Behrend, B., Ye, W., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100347
Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine
Kanoia, S. B., Tiwari, A., Rizvi, S. W. A., & Tiwari, A. (2026) · Journal of Pharmaceutical and Biopharmaceutical Research · doi:10.25082/jpbr.2026.01.004
“…daily without food or water restrictions, produced about 12% weight loss at 72 weeks at its highest dose in ATTAIN-1 [37] and was approved by the FDA for chronic weight management on 1 April 2026 [38]; an oral 25-mg formulation of semaglutide for weight management has also reached the market [39].”
Obesity: oral therapy for those afraid of needles
Vignera, S. L., & Condorelli, R. A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749645
Startschuss für die neue „Abnehmpille“
Bauer, E. (2026) · CME · doi:10.1007/s11298-026-4770-5
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Halpern, B., Baur, L. A., Blüher, M., Jackson-Morris, A. M., Ralston, J., & Ryan, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00234-2 · Cited by 1
Hoffmann, K., Pucek, W. F., Skrzypek, W., Kierzkowski, F., Ratajczak, P., Maggio, V., Rizzo, M., El-Tanani, M., Rabbani, S. A., Bhongade, B. A., et al. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.17560
“Peer-reviewed phase 3 evidence demonstrated clinically meaningful weight reduction in adults with overweight or obesity, while regulatory status was additionally documented by the manufacturer and regulatory sources [55, 56].”
Dose-response profiles in incretin and multi-agonist obesity pharmacotherapy
Yousefian, M., & Baharmast, M. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102947
Αλυμάρα, Β. Κ. (2026) · University of Thessaly Institutional Repository (University of Thessaly)
Pediatric obesity pharmacotherapy: a practical guide for general pediatricians
Mulvihill, H., Pliskin, L., Ponery, N., & Katzow, M. W. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001621
Wajid, R., Kumar, R., Muneer, M., Ali, M. N., Mustafa, J. U., Qamar, J., Asif, D., Ziaulhaque, S., Sohail, I., Khamisani, F. A., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02108-x
“However, in an exploratory leave-one-out sensitivity analysis of absolute weight change, heterogeneity decreased from I² 77% to I² 49% following exclusion of Wharton et al., 2025b [30].”
InfluentialNeue orale Adipositasmedikamente – Zukunft oder zweite Wahl?
Hauner, H. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02204-3
Australia is set to get a Wegovy pill. How does it compare with weight-loss injections?
Akrigg, K., Piatkowski, T. M., & Cornell, S. (2026) · The Conversation · doi:10.64628/aa.up343acn5
A Nature-Derived Peptide Promotes Satiety Hormone Response and Weight Loss In Vivo
Abramov, M. M., Goldfarb, E., Haham, D., Akiva, E., van Klinken, B. J., & Barbash, Z. (2026) · Journal of Dietary Supplements · doi:10.1080/19390211.2026.2752609
Metadata
- Authors
- Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T.
- Affiliations
- University of Toronto (CA)
- The University of Texas Southwestern Medical Center (US)
- Department of Treatment of Obesity, Metabolic Disorders, and Clinical Dietetics, Poznań University of Medical Sciences, Poznań, Poland
- Novo Nordisk, Søborg, Denmark
- Department of Internal Medicine, Endocrinology, and Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (India) (IN)
- Washington Center for Weight Management and Research (US)
- University of Alabama at Birmingham (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-09-18
- Volume
- 393
- Issue
- 11
- Pages
- 1077-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4414160143
- Cited by
- 142
- References
- 12
- Citations by year
- 2026: 127 · 2025: 15
- FWCI
- 79.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- oral semaglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, gastrointestinal adverse effects, lifestyle intervention, obesity-related comorbidities, non-diabetic adults, weight regain after weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Life Style, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.